Effect of erythromycin on homocysteine-induced extracellular matrix metalloproteinase-2 production in cultured rat vascular smooth muscle cells

Indian Journal of Medical Research

Volumn 121, Issue 6, 2005, Pages 764-770

  Guo, Hangyuan ^a   Lee, Jong Dae ^b   Yue, Hong ^b   Uzui, Hiroyasu ^b   Xing, Yangbo ^a   Wang, Junbo ^b   Toyoda, Kiyohiro ^b   Geshi, Tooru ^b   Ueda, Takanori ^b  

^a Department of Cardiology   (China)

^b UNIVERSITY OF FUKUI   (Japan)

Author keywords

Atherosclerosis; Erythromycin; Homocysteine matrix metalloproteinase; Smooth muscle cell

Indexed keywords

ERYTHROMYCIN; GELATINASE A; HOMOCYSTEINE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME SYNTHESIS; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; CELLS, CULTURED; ERYTHROMYCIN; HOMOCYSTEINE; MALE; MATRIX METALLOPROTEINASE 2; MUSCLE, SMOOTH, VASCULAR; RATS; RATS, SPRAGUE-DAWLEY;

EID: 22644431529     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
2. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-6.
3. Knoebel E, Vijayagopal P, Figueroa JE IInd, Martin DH. In vitro infection of smooth muscle cells by Chlamydia pneumoniae. Infect Immun 1997; 65: 503-6.
4. Blessing E, Lin TM, Campbell LA, Rosenfeld ME, Lloyd D, Kuo C. Chlamydia pneumoniae induces inflammatory changes in the heart and aorta of normocholesterolemic C57BL/6J mice. Infect Immun 2000; 68: 4765-8.
5. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105: 1298-303.
6. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Horne BD, Pearson RR, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: primary clinical results of the ACADEMIC study. Circulation 2000; 102: 1755-60.
7. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-83.
8. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11: 1157-68.
9. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-14.
10. Bescond A, Augier T, Chareyre C, Garcon D, Hornebeck W, Charpiot P. Influence of homocysteine on matrix metalloproteinase-2: activation and activity. Biochem Biophys Res Commun 1999; 263: 498-503.
11. Shapiro SD, Kobayashi DK, Ley TJ. Cloning and characterization of a unique elastolytic metalloproteinase produced by human alveolar macrophages. J Biol Chem 1993; 268: 23824-9.
12. Uzui H, Lee JD, Shimizu H, Tsutani H, Ueda T. The role of protein-tyrosine phosphorylation and gelatinase production in the migration and proliferation of smooth muscle cells. Atherosclerosis 2000; 149: 51-9.
13. Li Z, Li L, Zielke HR, Cheng L, Xiao R, Crow MT, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol 1996; 148: 121-8.
14. Gerritsen T, Waisman HA. Homocystinuria, an error in the metabolism of methionine. Pediatrics 1964; 33: 413-20.
15. D'Angelo A, Selhub J. Homocysteine and thrombotic disease. Blood 1997; 90: 1-11.
16. Woo DK, Dudrick SJ, Sumpio BE. Homocysteine stimulates MAP kinase in bovine aortic smooth muscle cells. Surgery 2000; 128: 59-66.
17. Mujumdar VS, Hayden MR, Tyagi SC. Homocysteine induces calcium second messenger in vascular smooth muscle cells. J Cell Physiol 2000; 183: 28-36.
18. Desai A, Lankford HA, Warren JS. Homocysteine augments cytokine-induced chemokine expression in human vascular smooth muscle cells: implications for atherogenesis. Inflammation 2001; 25: 179-86.
19. Vermeulen EG, Niessen HW, Bogels M, Stehouwer CD, Rauwerda JA, van Hinsbergh VW. Decreased smooth muscle cell/extracellular matrix ratio of media of femoral artery in patients with atherosclerosis and hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 2001; 21: 573-7.
20. Taha S, Azzi A, Ozer NK. Homocysteine induces DNA synthesis and proliferation of vascular smooth muscle cells by a hydrogen peroxide-independent mechanism. Antioxid Redox Signal 1999; 1: 365-9.
21. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, et al. Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996; 97: 146-53.
22. Lee HY, Chae IH, Kim HS, Park YB, Choi YS, Lee YW, et al. Differential effects of homocysteine on porcine endothelial and vascular smooth muscle cells. J Cardiovasc Pharmacol 2002; 39: 643-51.
23. Grayston JT. Antibiotic treatment trials for secondary prevention of coronary artery disease events. Circulation 1999; 99: 1538-9.
24. Parchure N, Zouridakis EG, Kaski JC. Effect of azithromycin treatment on endothelial function in patients with coronary artery disease and evidence of Chlamydia pneumoniae infection. Circulation 2002; 105: 1298-303.
25. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, et al. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998; 97: 633-6.
26. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-7.
27. Sinisalo J, Mattila K, Valtonen V, Anttonen O, Juvonen J, Melin J, et al. Effect of 3 months of antimicrobial treatment with clarithromycin in acute non-q-wave coronary syndrome. Circulation 2002; 105: 1555-60.
28. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
29. Stone AF, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, et al. Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation 2002; 106: 1219-23.